Sort
4,870 grants matching “glp 1”
Use of a GLP-1 Agonist to Treat Opioid Use Disorder in Rats and Man
$4,444,024Patricia Sue Grigson · Pennsylvania State Univ Hershey Med Ctr · UH3 · FY2025 · DA
ADME/FORMULATION Core
$4,224,287Sean B. Joseph · Scripps Research Institute, The · U19 · FY2022 · AI
FSH - an Aging Hormone?
$4,204,185Mone Zaidi · Icahn School Of Medicine At Mount Sinai · U19 · FY2024 · AG
Antibody-based therapy for fentanyl-related opioid use disorder
$4,202,550Rajeev Indrajit Desai · Mclean Hospital · UG3 · FY2023 · DA
Clinical Development of a Therapeutic Agent for Rapid Reversal of Methamphetamine Intoxication
$4,092,920Xinhua Li · Clear Scientific, Llc · U01 · FY2024 · DA
Clinical Development of a Therapeutic Agent for Rapid Reversal of Methamphetamine Intoxication
$4,069,920Xinhua Li · Clear Scientific, Llc · U01 · FY2023 · DA
FSH - an Aging Hormone?
$4,062,689Mone Zaidi · Icahn School Of Medicine At Mount Sinai · U19 · FY2025 · AG
Use of a GLP-1 Agonist to Treat Opioid Use Disorder in Rats and Man
$4,036,863Patricia Sue Grigson · Pennsylvania State Univ Hershey Med Ctr · UH3 · FY2024 · DA
CORE E: RNA Manufacturing Core
$4,002,763John P Cooke · Albert Einstein College Of Medicine · U19 · FY2025 · AI
Sustained Long Acting Prevention Against HIV Program Operation
$3,907,549Thomas Hope · Northwestern University At Chicago · UM1 · FY2016 · AI
LcrV Plague Vaccine with Altered Immune Modulatory Properties
$3,835,703Olaf Schneewind · University Of Chicago · U01 · FY2008 · AI
Clinical Development of a Therapeutic Agent for Rapid Reversal of Methamphetamine Intoxication
$3,799,875Xinhua Li · Clear Scientific, Llc · U01 · FY2025 · DA
A Phase I/IIa Clinical Trial Testing the Safety and Immunogenicity of a Heroin Vaccine and its Efficacy Against Morphine Challenge.
$3,797,321Gary R. Matyas · Henry M. Jackson Fdn For The Adv Mil/Med · UG3 · FY2019 · DA
A Phase I/IIa Clinical Trial Testing the Safety and Immunogenicity of a Heroin Vaccine and its Efficacy Against Morphine Challenge.
$3,690,224Gary R. Matyas · Henry M. Jackson Fdn For The Adv Mil/Med · UG3 · FY2018 · DA
Salivary Gland Secretion Mechanisms During Normal And Altered Functional States
$3,638,477Bruce J Baum · Dental & Craniofacial Research · Z01 · FY2007 · DE
Development of PPL-138, a Novel Mixed NOP/Mu Partial Agonist for Treatment of CocaineUse Disorder
$3,623,079Lawrence R Toll · Phoenix Pharmalabs, Inc. · U01 · FY2024 · DA
Sustained Long Acting Prevention Against HIV Program Operation
$3,609,469Thomas Hope · Northwestern University At Chicago · UM1 · FY2015 · AI
Development of SBI-553, an allosteric modulator of NTR1, for the treatment of substance use disorders
$3,588,880Michael Jackson · Sanford Burnham Prebys Medical Discovery Institute · UG3 · FY2019 · DA
National Islet Cell Consortium Coordinating Center
$3,572,923City Of Hope/Beckman Research Institute · U42 · FY2005 · RR
Novel, Non-Opioid, Non-Addictive Intrathecal Therapy for the Treatment of Chronic Pain
$3,539,507James N Campbell · Centrexion Therapeutics Corporation · UH3 · FY2024 · NS
HIV Subtype C Alphavirus Vaccine Design &Development
$3,529,060Alphavax Human Vaccines, Inc. · U01 · FY2003 · AI
Sustained Long Acting Prevention Against HIV Program Operation
$3,525,315Thomas Hope · Northwestern University At Chicago · UM1 · FY2017 · AI
Sustained Long Acting Prevention Against HIV Program Operation
$3,501,400Thomas Hope · Northwestern University At Chicago · UM1 · FY2018 · AI
Animal Medicine COVID Support
$3,453,487Mario Roederer · National Institute Of Allergy And Infectious Diseases · ZIG · FY2023 · AI
Development of a 3-month implantable depot pellet of Naltrexone for the treatment of Opioid Use Disorder.
$3,453,367Katherine Beebe Devarney · Biocorrx, Inc. · UH3 · FY2021 · DA